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PromoterThe level of glutathione transferase Kappa (GSTK1-1) has been correlated with obesity (Liu et.al. 2008 PNAS
105: 18302-7) and a polymorphism in the hGSTK1 promoter has been associated with insulin secretion and
fat deposition (Gao et al 2009 Endocr J 56: 487-94). We searched for additional polymorphisms that may
inﬂuence GSTK1-1 function or expression. Two SNPs were identiﬁed in the 5’ non-coding region. A SNP at
-1308 that occurs in Chinese subjects is predicted to eliminate a FXR/RXR transcription factor-binding site
and causes a 55% increase in transcription rate in HepG2 cells and a 59% decrease in HEK293 cells. These data
suggest that the impact of this polymorphism is complex and tissue speciﬁc. A SNP at -1032 alters a
methylation site and represses transcription by 38%. These observations provide the ﬁrst functional insight
into genetic factors that regulate hGSTK1 expression and may directly inﬂuence insulin secretion and fat
deposition.ision ofMolecular Biosciences,
anberra, ACT 2601, Australia.
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The Kappa class of glutathione S-transferases (GSTK) was ﬁrst
identiﬁed in mitochondrial matrix from rat liver [1]. Further studies of
human GSTK1-1 have conﬁrmed not only its mitochondrial localisa-
tion but also its presence in peroxisomes [2–4]. This deﬁned
subcellular localisation makes GSTK1-1 distinct from other soluble
GSTs that are found primarily in the cytosol.
Recent structural studies of GSTK proteins have shown that they
are more closely related to the bacterial proteins 2-hydroxychro-
mene-2-carboxylate (HCCA) isomerase and disulphide-bond-forming
oxidoreductase than to other cytosolic GSTs [5–7]. Despite structural
divergence, human GSTK1-1 does have signiﬁcant glutathione (GSH)
conjugating activity towards halogenated aromatics such as 1-chloro-
2,4- dinitrobenzene (CDNB) and some peroxidase activity with
organic hydroperoxides [4,5]. Although a preferred endogenous
substrate has not been identiﬁed, it has been speculated that
GSTK1-1 might be important in the maintenance of the redox balance
in subcellular organelles [4]. The knockdown of GSTK expression in
C elegans is reported to result in a signiﬁcant decrease in respiration
rate and a change in fatty acid metabolism [8]. Both observations are
consistent with a role in mitochondria and peroxisomes.
A role for GSTK1 in the post translational disulﬁde mediated
multimerization of adiponectin has been proposed and this isconsistent with the structural similarity between GSTK1-1 and the
disulﬁde bond forming protein (DsbA) in E.coli [9]. This study also
reported that GSTK1-1 (termed DsbA-L) expression in adipose tissue
was negatively correlated with obesity in humans and mice. Since
adiponectin expression has been correlated with insulin resistance,
obesity and diabetes [10–13] it is possible that the regulation of
GSTK1-1 expression may be an important factor in these metabolic
disorders. Signiﬁcantly, a polymorphism in the 5’ non-coding region of
the human GSTK1 gene (hGSTK1) was recently found to be associated
with insulin secretion and fat deposition in Chinese subjects [14].
Little is known about the hGSTK1 gene beyond its basic
organization and location on chromosome 7q34-35 [5]. In the light
of the previous reports implicating GSTK1-1 in the metabolic
regulation of obesity and diabetes, we have investigated the
frequency and function of polymorphisms in the hGSTK1 gene.
Althoughwe did not ﬁnd any genetic variation in the coding sequence
we identiﬁed two SNPs in the 5’ ﬂanking region (5'FR) that appear to
alter hGSTK1 transcription. In particular we found that the SNP studied
by Gao et.al. [14] disrupts an FXR(NR1H4)/RXR(RXRA) binding site
and has a strong but differing impact on basal level expression in
HepG2 and HEK293 cells.
Results
SNP discovery
In silico analysis of several databases revealed seven putative SNPs
within the protein coding region of GSTK1: three SNPs in the 5’
ﬂanking region (5'FR), plus nine SNPs in intronic and 3’ untranslated
Table 1













Frequency of variant allele
WT VAR European ancestory Chinese African
5'FR -1308 G T - sequencing rs1917760 ND* 0.20* ND*
5'FR -1032 G C - sequencing BsrBI 0.00 0.00 0.20
5'FR -765 G C - rs745890 ND ND ND
5'FR -255 T del - rs35125014 ND ND ND
Intron 1 C G - rs17164171 0.05* 0.00* 0.03*
Exon 4 317 T C V106A web trace BstU1 ND ND ND
Exon 4 347 A C K116T EST/blast BsmA1 ND ND ND
Exon 4 355 C G R119G EST/blast Xma1 ND ND ND
Exon 4 370 C T R124C EST/blast BstU1 ND ND ND
Intron 5 del T rs11296238 - - -
Intron 5 C T rs10275885 - - -
Intron 5 C T rs2367807 - - -
Intron 5 C T rs2367808 - - -
Intron 5 C T rs13311357 - - -
Exon 7 543 T A F181L EST/blast Bsu361 ND ND ND
Exon 7 549 C G L183L EST/blast Fnu4H1 ND ND ND
Intron 7 C G - rs7803893 0.00* 0.00* 0.08*
Exon 8 673 A G R225G web trace rs11552016 Hpa2 ND ND ND
Exon 8 707 C G rs1043436 - - -
Exon 8 777 A G - rs7786667 0.00* 0.00* 0.00*
1For 5’ ﬂanking and coding SNPs the position relative to the GSTK1 ATG is given along with amino acid change and diagnostic restriction digest where applicable. 2Polymorphisms
found by searching the dbSNP database [23], Genome Annotation Initiative (GAI) [31] database, alignments of expressed sequence tags or direct sequencing are listed. The numbers
given under mode of discovery refer to records in the NCBI dbSNP database; web trace indicates that a sequencing trace was found in the GAI database. *Starred frequencies indicate
genotyping data from the HapMap project [32]. ND indicates not detected in our study.
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selected for further study because it is possible to characterise their
effect on the GSTK1-1 activity or protein expression. Because
predicted coding region SNPs were in exons 4,7 and 8 these exons
were ampliﬁed from 194 individuals coming from ethnically diverse
backgrounds, including 94 Australian Caucasian, 50 African and 50
Southern Chinese individuals. The PCR products were then subjected
to restriction enzyme digestion to test for the predicted SNPs (see
Table 2). We were unable to conﬁrm any of these coding region SNPs
in our samples.
Approximately 1500 bp of the 5'FR for the hGSTK1 gene was
ampliﬁed from the DNA of 10 Australian Europeans, 10 Africans and
10 Southern Chinese individuals. These amplicons were sequenced to
validate the SNPs identiﬁed by in silico analysis and to potentiallyTable 2
Oligonucleotides used for PCR ampliﬁcation, sequencing, and electrophoretic mobility shift
Region Oligonucleotides1
Forward PCR primers Reverse P
5’ ﬂanking region -1556: ttctgccccagtttaggaga 49: ggaca
-1197: gccagctaaacaggagacca -726: attg
Exon 4 caaggaagagctagtcctc ctcacccttg
Exon 7 gtaactgctttctccaggc taacttactt
Exon 8 ctgagaacagtgtgcagag cgagtccca
Forward sequencing primers Reverse s
5’ ﬂanking region -486: agaattcaggcccctctcat -847: ctg





1Some of the oligonucleotides listed as being PCR primers were also used for sequencing. 2
position in bold and underlined. For the -1308 SNP the variant nucleotide is a T. FXR/RXRdetect additional novel polymorphisms. Two SNPs were identiﬁed by
this process, a transition of G to T was found at position -1308
(numbered from the ATG) in 2 Chinese subjects and a G to C transition
at -1032 was detected in 2 African individuals. No evidence was found
for the proposed G-C polymorphism at -765 (rs7458960) or the T
deletion at -255 (rs35125014) described in dbSNP build 125; see
Table 1.
The -1308 SNP has previously been described (rs1917760) with a T
allele frequency of approximately 0.20 in Asian populations. The -1032
SNP has not been previously reported. Genotype frequencies for the
-1032 SNP were conﬁrmed in Australian European, African and
Southern Chinese population samples (N=85, 69, and 64 respectively)
by BsrBI RFLP analysis. The C allele had a frequency of 0.20 in the African
population sample (see Table 1). Based on population speciﬁc genotypeassays (EMSA).
Restriction Enzymes RFLP temp
CR primers
gcacgtcatagaaga
catccccaaccaattagca BsrBI 37 °C
accagacg BstU1 60 °C
BsmA1 55 °C
Xma1 25 °C
acccagcagg Bsu361 37 °C
Fnu4H1 37 °C




The EMSA probes sequences shown are for the wild type sense probe with the mutant
indicates a consensus sequence for a prototypic FXR/RXR binding site.
Fig. 2. The hGSTK1 promoter was repressed by the farnesoid X receptor (FXR) agonist
chenodeoxycholic acid (CDCA). (A) Western blot showing endogenous expression of
FXR (top panel) and retinoid X receptor (RXR; bottom panel) in HepG2 and HEK293 cell
lines. The lane labelled RRL is a positive control showing the in vitro synthesis of the FXR
or RXR proteins using a rabbit reticulocyte lysate. HEKov indicates HEK293 cells which
are over-expressing recombinant FXR or RXR protein. HepG2* is an overexposure of the
ﬁlm to demonstrate the low levels of expression for endogenous FXR in the HepG2
cell line. (B) HepG2 cells which had been transfected with the WT-pXPG or -1308T
allele-pXPG constructs were treated with CDCA 24 hours after transfection. The
resulting luciferase activity has been standardised to the solvent control (treated with
50% DMSO). Values are the mean±SEM of at least triplicate data; stars indicate pb0.05
compared with the solvent control by ANOVA.
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polymorphisms in the immediate region spanning GSTK1.
Functional characterization of promoter variants
Luciferase reporter assays were used to determine if the 5'FR SNPs
cause changes in GSTK1 expression. The human kidney (HEK293) and
liver (HepG2) cell lines used in this study have been found to express
endogenous GSTK1-1 (Fig. 1A) and hence should contain appropriate
transcriptional elements needed to drive expression of the hGSTK1
promoter. As shown in Fig. 1B, the -1308T allele caused a 59% decrease
(p=0.002) in the HEK293 cell line and a 55% increase (p=0.054) in
HepG2 cells. The -1032 C allele caused at least a 38% decrease in
activity for both of the cell lines (pb0.001).
Characterisation of the -1308T allele
Analysis by MatInspector software [15] predicts that the -1308T
allele may eliminate a binding site for the retinoid X receptor (RXR)
and farnesoid X receptor (FXR) transcription factors. Western blot
analysis conﬁrmed that RXR and FXR are present in HEK293 and
HepG2 cells (Fig. 2A). RXRwas readily detected in HEK293 and HepG2
cells. In contrast endogenous FXR was not detectable in HEK293 cells;
expression of endogenous FXR in HepG2 was noted only when the
blot was exposed for an extended period (Fig. 2A). This conﬁrms a
report by Chen et al. [16] that FXR is expressed in HepG2 but not
HEK293 cells.
The data in Fig. 1 indicate that there are signiﬁcant allelic differ-
ences for GSTK1 promoter function in HEK293 and HepG2 cells. These
data suggest that FXR and RXRmay repress theWT GSTK1 promoter in
HepG2 cells. When the FXR/RXR binding site is modiﬁed by the -1308
SNP there is a signiﬁcant increase in luciferase activity implying that
the promoter is no longer repressed by transcription factors binding
to that site. To further examine this possibility we treated HepG2 cells
with the FXR agonist CDCA to ensure that FXR and RXR were being
actively expressed. As we expected CDCA caused further repression of
the WT GSTK1 promoter. Treatment with CDCA was dose responsive,
resulting in signiﬁcantly decreased levels of activity for the WT GSTK1
promoter (Fig. 2B). CDCA treatment also decreased activity of the
-1308 SNP construct by 20% (p=0.02; Fig. 2B) although this was notFig. 1. Variant hGSTK1 alleles inﬂuence promoter activity in the HepG2 and HEK293 cell
lines. (A) Western blot showing endogenous expression of GSTK1 in HepG2 and
HEK293 cells lines. (B) Relative luciferase activity for constructs containing either the
-1308T allele or -1032 C allele compared with the wild type (WT) construct. Error bars
indicate the SEM for a minimum of 3 independent assays. Starred bars indicate pb0.05
compared with the WT by ANOVA.dose responsive. This suggests that the -1308 SNP does not
completely eliminate FXR/RXR binding.
In contrast to the results obtainedwith HepG2 cells, the data in Fig. 1
indicate that the -1308T allele causes repression of luciferase activity in
HEK293 cells. This is not consistent with the results obtained with
HepG2 cells however this result may reﬂect the absence of FXR
expression in HEK293 cells.
To further evaluate whether the -1308 SNP modulates GSTK1
expression via RXR and FXR binding we investigated the binding of
GSTK1 WT and -1308 SNP DNA probes (see Table 2) to nuclear
proteins using electrophoretic mobility shift assays (EMSA; Fig. 3). A
FXR/RXR consensus sequence labelled with 32P was initially bound to
HEK293 and HepG2 nuclear proteins to determine which nucleopro-
tein complex had the same mobility as recombinant FXR and RXR
expressed using rabbit reticulocyte lysate (RRL) or overexpressed in
HEK293 cells (Fig. 3A; band marked F/R). Different mobility shift
patterns were noted in HEK293 and HepG2 cells indicating that there
are differences in the composition of the protein complexes that
interact with the FXR/RXR binding site in these cell lines.When GSTK1
WT or -1308 SNP DNA probes were bound to HEK293 and HepG2
nuclear proteins up to four additional complexeswere noted (Fig. 3B);
complex 1 was not apparent in HEK293 cells. The formation of many
of these complexes was prevented by addition of increasing amounts
of the RXR antibody (Fig. 3C; starred); presence of antibody also
caused a supershift for some of the upper bands. We were unable to
obtain similar results using a FXR antibody (data not shown).
Competition studies using up to 100 times excess of unlabelledWT
probe or an unlabelled -1308 SNP probe conﬁrmed the speciﬁcity of
these complexes (Fig. 3D). Interestingly no difference in the pattern of
nucleoprotein complexes was noted for the -1308 SNP DNA probe
(Fig. 3B) although there appears to be a difference in the relative
intensity for complex 1 and 2.
Fig. 3. FXR and RXR bind to a FXR/RXR binding site in the hGSTK1 promoter. Electrophoretic mobility shift assays (EMSA) were used to conﬁrm the binding of nuclear proteins to
oligonucleotides. (A) A 32P end-labelled double-stranded probe containing the consensus FXR/RXR binding sequence (Table 2) was incubated with nuclear extracts from the
HEK293 (HEK) and HepG2 (Hep) cell lines. Protein that had been synthesised in vitro using rabbit reticulocyte lysates (RRL) or nuclear extracts of the HEK293 cell line over-
expressing FXR or RXR were used as positive controls. The nucleoprotein complex identiﬁed in this gel as binding to FXR/RXR is marked F/R in all panels. (B) HepG2 and HEK293
nuclear extracts were incubated with a 32P end-labelled double-stranded probe containing either the GSTK1 WT FXR/RXR binding sequence (left) or this sequence modiﬁed to
contain the -1308 SNP (right). The resulting nucleoprotein complexes are labelled F/R or 1-4. Probe sequences are given in Table 2. (C) HepG2 nuclear extracts were preincubated
with RXR antibody for 30 min prior to addition of radiolabelled WT probe. NE indicates nuclear extract in the absence of antibody with subsequent lanes containing increasing
concentrations of antibody (Ab). * indicates the disappearance of complex in the presence of antibody while ↑ indicates supershift of high molecular weight complexes. (D) Nuclear
extracts from the HepG2 cell line were incubated with radiolabelled GSTK1WT probe. The speciﬁcity of binding was investigated by incubating the nuclear extract for 30 min (prior
to the addition of radiolabelled probe) with unlabelled oligonucleotide probes representing GSTK1WT, the -1308 SNP or an unrelated (NSP) probe. The respective probes are shown
in increasing concentration from left to right (at a ratio of 1:100, 1:10 and 1:1). In all panels labelled probe in the absence of a protein source is shown as a negative control (bl).
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Bioinformatic analysis of the region surrounding position -1032
did not predict any transcription factor binding sites in either the wild
type or variant sequences; however this SNP does appear to alter a
CpG methylation site. To investigate whether this SNP does introduce
a methylation site we used M.SssI CpG methylase to methylate
hGSTK1 WT and -1032 SNP DNA fragments. Differences in DNA
fragments after digestion with the methylation sensitive enzyme AciI
indicated that the variant allele is susceptible to methylation (Fig. 4A).
In other data not shown we found that global methylation of the
1500 bp GSTK1 promoter caused almost complete repression of both
the wild type and variant -1032 C alleles. This data suggests that
hGSTK1 promoter activity can be globally inﬂuenced by methylation
but does not explain the speciﬁc repression observed for the -1032 C
allele in Fig. 1.
Discussion
The GSTK1 gene is approximately 5.7 kb in size with 8 exons and 7
introns [5]. Databases predict seven polymorphisms in the coding
region, three within the 5’ ﬂanking region (1600 bp of 5'FR includingthe 5'UTR) plus nine in intronic and 3'UTR regions. To maximise
success in verifying them we deliberately chose SNPs that were
present in two or more EST sequences or where there was clear
experimental evidence, such as a peak present in a sequencing trace.
We genotyped the coding region and 5'FR SNPs and were able to
verify only one of the 5'FR region SNPs (rs1917760). The HapMap
project was similarly unable to verify a 3'UTR SNP (rs7786667) in a
population comprising of individuals from Yoruba African (60),
Japanese (44), Han Chinese (45) and Caucasian American (59)
backgrounds. These results highlight the number of data-mined
SNPs that are difﬁcult to conﬁrm. It has been estimated that
approximately half of the SNPs found in databases, such as dbSNP,
have not been independently validated [17,18].
It is interesting that so few SNPs were found in the GSTK1 gene.
Many estimates have been made for SNP density in the human
genome with one SNP every 1000 base pairs being a commonly
quoted value [19]. Large resequencing studies suggest that this ﬁgure
is closer to 1 SNP every 500 bp howevermost of these SNPs have allele
frequencies of less than 5% and 96% of them are found in the non-
coding regions of the gene [20]. Without entirely resequencing the
GSTK1 gene in a large number of subjects to obtain a complete survey
Fig. 4. The SNP at -1032 in the GSTK1 promoter changes a methylation site. (A) Differences in methylation status were demonstrated by in vitro methylation of the GSTK1 WT and
-1032 SNP promoters followed by overnight restriction digestion with Bgl2 and AciI. Methylation (m) blocked the AciI restriction site to give the same electrophoresis pattern for
both the WT and SNP constructs. (B) Schematic showing the expected banding patterns for an AciI/Bgl2 restriction digest before and after methylation. Bands less than 200 bp are
not visible on this gel.
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estimate SNP density for GSTK1. However with no SNPs validated in
the coding region and only 4 SNPs seen in non-coding regions in four
ethnically distinct populations (present results and HapMap data), it
appears that GSTK1 has fewer than the average 4.6 SNPs per kilobase
estimated in 75 genes by Halushka et al [21].
Our studies conﬁrmed the presence of two SNPs in the 5'FR. The G
to T transition at -1308 that was previously studied by Gao et al [14] in
relation to diabetes has only been observed in Chinese subjects so far.
The second 5'FR SNP at -1032 was discovered by direct sequence
analysis and was only found in African subjects.
The T allele at -1308 resulted in an increase in expression for
HepG2 cells and a signiﬁcant reduction in expression for HEK293 cells.
This striking difference in response between cell lines suggests that
this SNP may be an important genetic regulator of GSTK1-1
expression with effects on downstream processes that are modulated
by GSTK1-1. This is consistent with the proposed role for GSTK1-1 in
the post-translational processing of adiponectin, its association with
obesity [9] and the association of this variant GSTK1 allele with insulin
secretion and fat deposition [14]. As a consequence of its position the
-1308T allele may disrupt an FXR/RXR transcription factor-binding
site. We found differences in the expression of FXR and RXR between
HepG2 and HEK293 cells and these may contribute towards the
differences in hGSTK1 promoter activity that we observed. However
repression of the -1308T allele by CDCA indicates that it is still a
functional FXR/RXR binding site and EMSA studies found that the
-1308T allele binds to the FXR/RXR nucleoprotein complex and can
compete successfully with the wild type -1308 C allele. Additionally
the presence of multiple nucleoprotein complexes binding to this
transcription factor binding site suggests that it may not be
exclusively binding to FXR and RXR. Clearly this FXR/RXR binding
site is important in the regulation of GSTK1 expression but its role is
complex and may vary considerably in different tissues.
FXR plays an essential role in the control of bile acid synthesis and
in partnership with the transcription factors peroxisome proliferator-
activated receptor (PPARA), vitamin D receptor (VDR), pregnane X
receptor (NR1I2), constitutive andosterone receptors (NR1I3) and
liver X receptor (NR1H2) also helps to regulate lipid homeostasis [22].
Analysis of the hGSTK1 promoter region has identiﬁed at least one
binding site for each of these transcription factors in the 5'FR. Given
the subcellular localisation of GSTK1-1 to mitochondria and the
peroxisome [4], and the association of GSTK knock down and fatty
acid metabolism in C. elegans [8] it is conceivable that GSTK1-1 is also
involved in this regulatory cascade.
The C allele at -1032 decreased luciferase activity by approxi-
mately 40% when compared to the WT construct. We were able to
demonstrate the presence of an additional methylation site in the
-1032 C allele versus theWT allele using in vitromethylation followedby methylation sensitive restriction digest. However, when in vitro
methylated plasmids were used to drive luciferase expression the WT
and SNP constructs were equally repressed suggesting that the
hGSTK1 promoter can be silenced by more global methylation. If this
site plays a role in the regulation of hGSTK1 expression it may be the
subject of site speciﬁc methylation.
This study investigated the polymorphisms in the hGSTK1 gene
and only found two SNPs in the 5'FR. We found functional differences
between these SNPs and the common wild type allele. In addition we
were able to demonstrate that the promoter region can be repressed
by methylation and chenodeoxycholic acid. These observations
provide the ﬁrst functional insight into the genetic factors that
regulate GSTK1-1 expression and the potential mechanism by which
the -1308T allele inﬂuences insulin secretion and fat deposition.
Materials and methods
Study population
The genomic DNA samples were studied with the approval of the
Human Ethics Committee of the Australian National University and
were obtainedwith informed consent from normal blood donors after
ethics approval by local blood transfusion authorities in Canberra
Australia, Durban South Africa and Hong Kong China.
Polymorphism identiﬁcation and analysis
Putative SNPs in the humanGSTK1 genewere identiﬁed by analysis
of web-based sequence and polymorphism databases as previously
described [23–25]. For promoter region SNP discovery, 1500 bp of
hGSTK1 5'FR DNA was ampliﬁed and sequenced from 10 Australian
European, 10 African and 10 Southern Chinese individuals. Conﬁrma-
tion of novel SNPs in the coding region or in the 5'FR was undertaken
by PCR followed by restriction fragment length polymorphism (RFLP;
see Table 2) analysis in up to 100 individuals from each ethnic group.
Primers for the ampliﬁcation of the hGSTK1 exons or regions of the
promoter were purchased from Sigma-Proligo (Castle Hill, NSW) and
are listed in Table 2. SNPs found in the 5'FR were screened for changes
in putative transcription factor binding sites using MatInspector [15].
Potential methylation sites were identiﬁed using Methylator [26].
Promoter function assays
Approximately 1500 bp of the wild type (WT) 5'FR of hGSTK1
including the untranslated region of exon 1 was ampliﬁed using Pfu
Turbo (Stratagene, La Jolla CA) and subcloned into the pXPG ﬁreﬂy
luciferase reporter plasmid [27]. Variant alleles were either generated
using site-directed mutagenesis as described by Ho et al. [28] or by
304 A.J. Shield et al. / Genomics 95 (2010) 299–305subcloning the variant allele from an affected individual. The integrity
of the constructs was veriﬁed by sequence analysis undertaken in the
Biomolecular Resource Facility at the John Curtin School of Medical
Research.
These reporter constructs (200 ng per well) were used to transfect
the HEK293 and HepG2 cell lines using Lipofectamine 2000 according
to the manufacturers protocol (Invitrogen, Mount Waverley VIC).
Cells (2×104) were co-transfected in quadruplicate with 20 ng
plasmid encoding Renilla luciferase (pTK-RL; Promega, Sydney
NSW) to control for transfection efﬁciency. After 48 hr cells were
assayed for luciferase activity using the Dual-Glo Luciferase Assay
System (Promega, Sydney NSW) as described by the manufacturer.
Each experiment was repeated at least three times independently and
differences in luciferase activity were evaluated using either t-tests or
ANOVA where applicable.
Protein synthesis and Western Blot analysis
The FXR and RXR proteins were synthesised using the TNT Coupled
Reticulocyte Lysate System according to the manufacturers’ instruc-
tions (Promega, Sydney NSW). Brieﬂy, pCMX-FXR or pCMX-RXR
expression vectors (from Dr David Mangelsdorf at UT Southwestern
Medical Centre) were combined with TNT rabbit reticulocyte lysate
(RRL), TNT T7 RNA polymerase, 40 nM amino acid mix, and RNasin
ribonuclease inhibitor at 30 °C for 90 min. [35S]methionine was added
to a proportion of the reaction as a positive control. These expression
constructs were also used to transfect the HEK293 cell line using
Lipofectamine 2000. Protein synthesis was checked by SDS-PAGE of
the 35S labelled reactions orWestern Blot. Antibodies forWestern Blot
included rabbit anti-RXR (ΔN 197; sc-774) and goat anti-FXR (C-20;
sc-1204) (Santa Cruz Biotechnology, Santa Cruz CA). For GSTK1,
polyclonal antiserum was prepared in rabbits by immunization with
recombinant human GSTK1-1 that had been expressed in E. coli and
puriﬁed by means of an N-terminal His tag [5]. The speciﬁcity of the
antiserum was conﬁrmed on a Western blot against puriﬁed
recombinant GSTK1-1 (data not shown).
Electrophoretic Mobility Shift Assays (EMSA)
Nuclear extracts were prepared from HEK293 and HepG2 cell lines
using a modiﬁed salt extraction method [29]. Cells at 80% conﬂuence
were harvested, pelleted by centrifugation at 1000×g for 5 min and
then washed in phosphate-buffered saline. Cell pellets were then
resuspended in 10 mM HEPES buffer (pH 7.9) containing 10 mM KCl,
0.1 mM EDTA, 0.1 mM EGTA, 0.4% NP40, 0.5 mM AEBSF (ICN
Biomedical, Seven Hills, NSW) and 1 mM DTT, and incubated on ice
for 15 min. The nuclear pellet was spun down for 30 sec and washed
in 1 ml of the HEPES buffer described above. The nuclear pellet was
resuspended in 20 mM HEPES buffer (pH 7.9) containing 400 mM
NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT and 0.5 mM AEBSF and
mixed on a rotary wheel for 15 min at 4 °C. Cellular debris was
pelleted by centrifugation and the supernatant stored at -20 °C until
use.
Double stranded oligonucleotides used as probes (Table 2) were
generated by 5'end labelling 100 ng single stranded oligonucleotide
with [γ-32P]dATP (PerkinElmer, Rowville VIC) using T4 polynucleo-
tide kinase (New England Biolabs, Ipswich MA). Labelled single
stranded oligonucleotides were puriﬁed using QIAQUICK Nucleotide
removal kit (QIAGEN, Doncaster, VIC) and allowed to anneal with the
complementary oligonucleotide at room temperature for 10 min.
Double stranded labelled probe was incubated with 5 μg of nuclear
extract (or 10 μL RRL) for 30 min at room temperature in 20 mM
HEPES pH 7.9, 5% glycerol, 1 mM EDTA, 1% NP40, 5 mMDTT, 1 mg/mL
BSA, and 1 μg poly(dI-dc). Samples were resolved on a 5% non-
denaturing polyacrylamide gel; these gels were dried and subjected to
autoradiography. For antibody and probe competition studies, 1-2 μLof antibody or 1 μL of unlabeled probe was incubated with the nuclear
extract for 30 min prior to the addition of the radiolabelled probe. Non
speciﬁc probes (NSP) were randomly generated and checked to
ensure that they contained no putative transcription factor binding
sites using MatInspector [15].
Methylation analysis
The pXPG reporter constructs were transformed into E.coli strain
JM110 to remove the potential for bacterial methylation of the
constructs. The WT and -1032 SNP alleles were then excised from the
vector and gel puriﬁed. Puriﬁed inserts or whole plasmid were in vitro
methylated using the CpG Methylase, M.SssI (NEB) for 6 hrs at 37 °C.
Similar to the mammalian enzyme Dnmt1, M.SssI methylates cytosine
in the CpG dinucleotide [30]. Methylated and non-methylated DNA
was digested overnight at 37 °C using a methylation sensitive
restriction enzyme (BsrBI or AciI) and the restriction enzyme Bgl2
that is not inﬂuenced by methylation status. Methylation status was
determined by analysis of digestion patterns on a 1.5% agarose gel.
Where treated DNA was used for transfection, plasmids were puriﬁed
using the Wizard SV Gel and PCR clean-up system (Promega, Sydney
NSW).
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